Congress trading in GILD
26 members of Congress have disclosed trading GILD — 25 purchases and 18 sales worth an estimated $658,000. Most recent disclosure: May 6, 2026.
See who in Congress traded GILD →About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Key Statistics
GILD in plain English
- P/E ratio (17.4) — how many dollars you pay for each $1 of GILD's yearly profit. That's a fairly normal range.
- ROE (43.36%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (30.99%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.56%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
Compare GILD with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.